Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Ítems similars

• Potential applications of Bruton’s tyrosine kinase inhibitors for the prevention of allergic reactions
  per: Dispenza, Melanie C., et al.
  Publicat: (2017)
• Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy
  per: Dispenza, Melanie C., et al.
  Publicat: (2018)
• The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
  per: Dispenza, Melanie C.
  Publicat: (2021)
• Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
  per: Woyach, Jennifer A., et al.
  Publicat: (2014)
• Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
  per: Noy, Ariela, et al.
  Publicat: (2017)